Coronary Artery DiseaseSilent myocardial ischemia and microalbuminuria in asymptomatic subjects with non–insulin-dependent diabetes mellitus☆
Section snippets
Patient selection
NIDDM patients (according to World Health Organization criteria), aged 45 to 75 years, were recruited from hospital diabetic clinics in Newcastle upon Tyne, United Kingdom. Exclusion criteria were: NIDDM for <1 year, history of myocardial infarction, history of angina, as defined by the Rose questionnaire,12 heart failure, uncontrolled hypertension (blood pressure >180/100 mm Hg), significant aortic stenosis, cardiomyopathy, known serious arrhythmias, left bundle branch block, previous coronary
Clinical and biochemical characteristics
The success of the matching was demonstrated by no significant differences in age, gender, known diabetes duration, or smoking status between groups (Table I). Clinical assessment showed that patients with microalbuminuria were more likely to have symptoms of intermittent claudication, peripheral neuropathy, and a history of higher alcohol intake than those with normoalbuminuria. Those with microalbuminuria also had increased body mass index, waist hip ratio, systolic blood pressure, and
Discussion
We have shown that silent myocardial ischemia is common in asymptomatic NIDDM patients both with (65%) and without microalbuminuria (40%), but in those with microalbuminuria, it is more common and occurs at lower workloads. We have demonstrated that in asymptomatic NIDDM patients, the presence of microalbuminuria is the strongest independent predictor of ischemic response on treadmill exercise testing.
References (27)
- et al.
Significance of silent myocardial ischemia during exercise testing in patients with diabetes mellitusa report from the Coronary Artery Surgery Study (CASS) Registry
Am J Cardiol
(1991) - et al.
Detection of silent myocardial ischemia in diabetes mellitus
Am J Cardiol
(1991) - et al.
Silent myocardial ischemia in patients with non-insulin-dependent diabetes mellitus as judged by treadmill exercise testing and coronary angiography
Am Heart J
(1992) - et al.
Coronary heart disease morbidity and mortality in hypercholesterolemic men predicted from an exercise testthe Lipid Research Clinics Coronary Primary Prevention Trial
J Am Coll Cardiol
(1989) - et al.
Silent myocardial ischemia and infarction in diabetics with peripheral vascular diseaseassessment by dipyridamole thallium-201 scintigraphy
Am Heart J
(1990) - et al.
Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischemia. The Research Group on Instability in Coronary Artery Disease in Southeast Sweden
Lancet
(1992) - et al.
Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemiaresults of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography
J Am Coll Cardiol
(1994) - et al.
Improvement of silent myocardial ischemia and reduction of plasma fibrinogen during nisoldipine therapy in occult coronary arterial disease
Int J Cardiol
(1991) - et al.
Attenuation of the circadian patterns of myocardial ischemia with nifedepine GITS in patients with chronic stable angina
J Am Coll Cardiol
(1992) - et al.
Beneficial effect of oestrogen on exercise induced myocardial ischemia in women with coronary artery disease
Lancet
(1993)
Asymptomatic Cardiac Ischemia Pilot (ACIP) studyoutcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. The ACIP Investigators
J Am Coll Cardiol
Diabetes and cardiovascular disease. The Framingham study
JAMA
Silent Myocardial Ischemia and Infarction
Cited by (80)
Screening for the Presence of Cardiovascular Disease
2018, Canadian Journal of DiabetesCitation Excerpt :Myocardial ischemia (whether silent or symptomatic) detected during exercise stress testing in individuals with diabetes is associated with poorer long-term survival compared to individuals without diabetes (16). Silent MI is common (40%) in older asymptomatic individuals with type 2 diabetes, but is more frequent (65%) in those with diabetes who also have microalbuminuria (35). People with diabetes and silent ischemia have an annual event rate for CAD of 6.2% (50% of events were new-onset angina and 50% were cardiac death or MIs) (36).
Cardiovascular disease in diabetes
2018, Encyclopedia of Endocrine DiseasesPredictors and prognostic impact of silent coronary artery disease in asymptomatic high-risk patients with diabetes mellitus
2017, International Journal of CardiologyCitation Excerpt :The predictive role of an increased BNP-value at baseline is in line with results of a primary prevention study in which BNP was used to identify end organ damage of the heart: in asymptomatic primary prevention patients, BNP screening was able to identify silent heart disease [17]. On the other side and in contrast to several other studies [18,19], neither an increased creatinine level nor the presence of microalbuminuria were independently predictive of an abnormal MPS in the present analysis. This may be explained partly by the frequent use of ACE-/ARB-inhibitors (77%), the highly selected patient group tested and the multiple predictors analysed in the current versus older studies [15,18].
Chest Pain
2015, Murray and Nadel's Textbook of Respiratory Medicine: Volume 1,2, Sixth EditionDépistage de la coronaropathie
2013, Canadian Journal of DiabetesCitation Excerpt :Chez les personnes diabétiques, une ischémie myocardique (silencieuse ou symptomatique) décelée pendant une épreuve d’effort est associée à une moindre survie à long terme, comparativement à celle observée chez les personnes non diabétiques (7). Une ischémie myocardique (IM) silencieuse est courante (40 %) chez les personnes plus âgées souffrant de diabète de type 2, mais elle est plus fréquente (65 %) chez les personnes diabétiques présentant également une microalbuminurie (19). Les personnes souffrant de diabète et d’ischémie silencieuse présentent un taux annuel d’événements coronariens de 6,2 % (dans la moitié [50 %] des cas, il s’agissait d’une angine d’apparition nouvelle, et dans l’autre moitié [50 %], d’un décès d’origine cardiaque ou d’une IM) (20).
Screening for the Presence of Coronary Artery Disease
2013, Canadian Journal of Diabetes
- ☆
This study was supported by grants from The Northern Region Small Grants Committee, The Freeman Hospital Board of Trustees, Newcastle upon Tyne, United Kingdom; Novo Nordisk, Crawley, West Sussex; Bayer plc, Newbury, Berkshire; and Eli Lilly and Co. Ltd., Basingstoke, Hampshire, United Kingdom.